IP Library Granted Patent US 11,590,125
Granted Patent B2
US 11,590,125 · App. 17/007,902 · Granted Feb 28, 2023

Levocetirizine and montelukast in the treatment of inflammation mediated conditions

Inventor: Bruce Chandler May (Santa Barbara, CA)
Assignee: IRR, Inc.
A61K31/495A61K31/47A61K45/06A61P25/00A61P25/16A61P25/28Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,590,125
App. No.
17/007,902
Granted
Feb 28, 2023
Kind
B2
Abstract

The embodiments described herein include methods and formulations for treating viruses and diseases that are exacerbated by inflammatory responses in the body. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.

Claims (11)

1. A method of treating an inflammatory NFκB-mediated neurological condition, the method comprising administering to a patient an effective amount of a combination of levocetirizine and montelukast.

2. The method of claim 1 , wherein the condition is selected from the group consisting of Alzheimer's disease, dementia, dementia with Lewy bodies, Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia, and Huntington's disease.

3. The method of claim 1 , wherein the combination of levocetirizine and montelukast is administered in a sequential manner.

4. The method of claim 1 , wherein the combination of levocetirizine and montelukast is administered in a substantially simultaneous manner.

5. The method of claim 1 , wherein the combination is administered to the patient by one or more of the routes consisting of enteral, intravenous, intraperitoneal, inhalation, intramuscular, subcutaneous and oral.

6. The method of claim 5 , wherein the levocetirizine and montelukast are administered by the same route.

7. The method of claim 5 , wherein the levocetirizine and montelukast are administered via different routes.

8. The method of claim 1 , wherein the combination is administered to the patient intravenously.

9. The method of claim 1 , wherein one or more of levocetirizine or montelukast are provided as a slow release composition.

10. The method of claim 2 , wherein the combination further comprises other medications known for use in treating one of the listed conditions.

11. The method of claim 1 , wherein the combination further comprises a steroid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2022
From: MAY, BRUCE CHANDLER
To: IRR, INC.
Reel/Frame 061644/0304 →
Continuity (6)
Continuation 16224573 · Dec 18, 2018
Continuation 15895918 · Feb 13, 2018
Continuation 15450840 · Mar 6, 2017
Continuation PCTUS2015049767 · Sep 11, 2015
Provisional Application 62050668 · Sep 15, 2014
Related Publication 20210177835A1 · Jun 17, 2021
Cited By (1)
US 12,514,855